Complete Omics Inc. Complete Omics Inc. Complete Omics Inc. Complete Omics Inc.
  • Home
  • About
    • Our Impact
    • Our Team
  • Clinical
    • Column

      Clinical Multi-Omics

      • Clinical Proteomics
        • Complete360® Plasma Proteomics and Diagnostics
        • Valid-NEO® Neoantigen Validation and Clinical Companion Diagnostics
      • Clinical Multi-Omics Services
        • CompleteCohort® Large Cohort Multi-Omics

      Our Latest News In Clinical Applications

      Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments

      February 28, 2022
      Read More »

      Identifying and Quantifying Neoantigens derived from Human endogenous retroviruses (HERVs) — A new class of targets to expand the benefits of cancer immunotherapy.

      January 29, 2022
      Read More »

      Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media

      March 15, 2021
      Read More »
  • Research
    • Column

      Proteomics

      • Qualitative Proteomics
        • Proteome Profiling
        • De novo Antibody Sequencing
        • Protein Identification and Mapping
      • PTM Proteomics
        • PhosphoProteomics
        • GlycoProteomics
        • Ubiquitination Proteomics
        • Other PTMS
      • Immunoprecipitated Profiling and Quantification

        

      • Quantitative Proteomics
        • TMT, iTRAQ, SILAC and other Label-dependent Quantification
        • SRM / MRM / PRM Absolute Quantification
        • Label-free Quantification
      • Specialized Services
        • Host Cell Protein Analysis

      Genomics

      • Damaged Sample NGS
        • FFPE, Plasma, Fossil, Ancient and Damaged Sample
        • ChIP-Seq
        • Single Cell Sequencing
        • Methyl-Seq
      • Conventional NGS
        • Genome / Exome-Seq, Targeted Seq, RNA-Seq

      Metabolomics

      • Targeted Metabolomics
        • Targeted detection and quantification of vitamins, amino acids, hormones and 3,000+ kinds of small molecules
      • Untargeted Metabolomics
        • Complete profiling of water/lipid-soluble metabolite molecules
      • Lipidomics (ID and Quant)

      Single Cell Omics

      • Single Cell Proteomics
        • Antibody-independent Single Cell Proteomics Assays — Profiling Assay and Targeted Detection
      • Single Cell Genomics
        • Single Cell RNA-Seq and Genomics Assay — Signaling Pathway Assays and Genomic Changes
      • — All single cell services are conducted by leading experts through singlecell.com —

      Select Notable Projects

      List of Notable Projects
  • News
  • Contact

Our News

MT-SRM, direct detection of mutant proteins as cancer-specific biomarkers

February 2, 2019

SAFE-SRM is the 1st pipeline built for clinical proteomics-based cancer diagnostics. It established a pipeline for cancer diagnostics through monitoring proteomic biomarkers, and for high throughput validation of potential biomarkers.

Read More »
« Previous Page1 Page2 Page3 Page4 Next »

About Complete Omics

 

 

We are on Twitter

  • Identifying and Quantifying Neoantigens derived from Human endogenous retroviruses (HERVs) — A new class of targets… https://t.co/jMIgXUQ7dZ 3 years ago
  • https://t.co/T6hJY3bEkZ https://t.co/lAbMY8INWJ 4 years ago
Follow @completeomics

News

  • Milestone! | Complete Omics Inc. Secures California Clinical Laboratory License, Expanding Access to Cutting-Edge Clinical Proteomics Testing
    February 21, 2025
  • Milestone! | Complete Omics Inc. Achieves CLIA, CAP Certification, and Medicare Enrollment
    October 20, 2024

All Rights Reserved

  • Payment Terms
  • Privacy Policy

Your ticket for the: Our News

Title

Our News

USD

Follow by Email
Facebook
Twitter
LinkedIn